Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, Pan Chin-Chen, Netto G, Doglioni C, Hes O, Argani P, Chilosi M
Anatomia Patologica, Università di Verona, Verona, Italy.
Mod Pathol. 2009 Aug;22(8):1016-22. doi: 10.1038/modpathol.2009.58. Epub 2009 Apr 24.
The microphthalmia transcription factor/transcription factor E (TFE)-family translocation renal cell carcinomas bear specific translocations that result in overexpression of TFE3 or TFEB. TFE3 fusion gene product overexpression occurs as consequence of different translocations involving chromosome Xp11.2, whereas TFEB overexpression is the result of the specific translocation t(6;11)(p21;q12), which fuses the Alpha gene to TFEB. Both TFE3 and TFEB are closely related members of the microphthalmia transcription factor/TFE-family, which also includes TFEC and microphthalmia transcription factor. These transcription factors have overlapping transcriptional targets. Overexpression of microphthalmia transcription factor has been shown to mediate the expression of cathepsin-K in osteoclasts. We hypothesize that the overexpression of the related TFE3 fusion proteins and TFEB in translocation renal cell carcinomas may have the same effect. We studied cathepsin-K in 17 cytogenetically confirmed microphthalmia transcription factor/TFE-family translocation renal cell carcinomas. Seven cases showed a t(6;11)(p21;q12), ten cases showed translocations involving Xp11.2; five cases t(X;1)(p11;q21) resulting in a PRCC-TFE3 gene fusion; three cases t(X;1)(p11;p34) resulting in a PSF-TFE3 gene fusion, one t(X;17)(p11;q25) resulting in an ASPL-TFE3 gene fusion, and one t(X;3)(p11;q23) with an unknown TFE3 gene fusion. As control we analyzed cathepsin-K in 210 clear cell, 40 papillary, 25 chromophobe renal cell carcinomas and 30 oncocytomas. All seven TFEB translocation renal cell carcinomas were labeled for cathepsin-K. Among the cytogenetically confirmed TFE3 translocation renal cell carcinomas, 6 out of 10 were positive. None of the other renal neoplasms expressed cathepsin-K. We conclude the following: (1) cathepsin-K is consistently and strongly expressed in TFEB translocation renal cell carcinomas and in 6 of 10 TFE3 translocation renal cell carcinomas. (2) Cathepsin-K immunolabeling in both TFE3 and TFEB translocation renal cell carcinomas distinguishes these neoplasms from the more common adult renal cell carcinomas, and may be a specific marker of these neoplasms. (3) These results further support the concept that the overexpression of TFE3 or TFEB in these neoplasms activates the expression of genes normally regulated by microphthalmia transcription factor in other cell types.
小眼畸形转录因子/转录因子E(TFE)家族易位性肾细胞癌具有特定的易位,导致TFE3或TFEB的过表达。TFE3融合基因产物的过表达是涉及Xp11.2染色体不同易位的结果,而TFEB的过表达是特定易位t(6;11)(p21;q12)的结果,该易位将Alpha基因与TFEB融合。TFE3和TFEB都是小眼畸形转录因子/TFE家族的密切相关成员,该家族还包括TFEC和小眼畸形转录因子。这些转录因子具有重叠的转录靶点。小眼畸形转录因子的过表达已被证明可介导破骨细胞中组织蛋白酶K的表达。我们假设相关的TFE3融合蛋白和TFEB在易位性肾细胞癌中的过表达可能具有相同的作用。我们研究了17例经细胞遗传学证实的小眼畸形转录因子/TFE家族易位性肾细胞癌中的组织蛋白酶K。7例显示t(6;11)(p21;q12),10例显示涉及Xp11.2的易位;5例t(X;1)(p11;q21)导致PRCC-TFE3基因融合;3例t(X;1)(p11;p34)导致PSF-TFE3基因融合,1例t(X;17)(p11;q25)导致ASPL-TFE3基因融合,1例t(X;3)(p11;q23)伴有未知的TFE3基因融合。作为对照,我们分析了210例透明细胞、40例乳头状、25例嫌色性肾细胞癌和30例嗜酸细胞瘤中的组织蛋白酶K。所有7例TFEB易位性肾细胞癌均被标记为组织蛋白酶K阳性。在经细胞遗传学证实的TFE3易位性肾细胞癌中,10例中有6例为阳性。其他肾肿瘤均未表达组织蛋白酶K。我们得出以下结论:(1)组织蛋白酶K在TFEB易位性肾细胞癌以及10例TFE3易位性肾细胞癌中的6例中持续且强烈表达。(2)TFE3和TFEB易位性肾细胞癌中的组织蛋白酶K免疫标记将这些肿瘤与更常见的成人肾细胞癌区分开来,可能是这些肿瘤的特异性标志物。(3)这些结果进一步支持了这样的概念,即这些肿瘤中TFE3或TFEB的过表达激活了其他细胞类型中通常由小眼畸形转录因子调节的基因的表达。